In this episode of "The Top Line," we talk with Fierce’s Max Bayer and Angus Liu about the most important news coming from this year's annual BIO conference. We also cover a COVID lawsuit, an FDA-approved app, and the rest of the week's headlines. 

To learn more about the topics in this episode:
ASCO: After lung cancer fails, Roche's faith in TIGIT rewarded as tiragolumab shows signs of life in liver cancer
Merck ends last Keytruda trial in aggressive prostate cancer campaign, takes separate hit in lung cancer
Roche, with HER2 franchise under pressure, pays $70M for breast cancer brain metastases prospect
Takeda pledges up to $1.13B for rights to Hutchmed's cancer drug fruquintinib outside of China
BIO: Moderna to test mpox vaccine in humans this summer
BIO: Jazz is auditioning new bandmates in an M&A market ripe with talent
BioNTech to defend itself against COVID-19 vaccine injury claim in Germany
Salvation or 'death warrant'? Erytech's war with activist investor rumbles on as merger vote nears
RSV vaccine awareness low among older adults, but majority would ask their doc about new shots: survey
Huma nabs FDA nod for AI-backed disease management platform
Medtronic warns cardioversion can fry some Vanta neurostimulators

"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

In this episode of "The Top Line," we talk with Fierce’s Max Bayer and Angus Liu about the most important news coming from this year's annual BIO conference. We also cover a COVID lawsuit, an FDA-approved app, and the rest of the week's headlines. 
To learn more about the topics in this episode:
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/after-lung-cancer-fails-roches-tigit-candidate-shows-promise-liver">ASCO: After lung cancer fails, Roche's faith in TIGIT rewarded as tiragolumab shows signs of life in liver cancer</a></li>
<li><a href="https://www.fiercepharma.com/pharma/merck-caps-last-keytruda-study-aggressive-prostate-cancer-expedition-takes-hit-lung-cancer">Merck ends last Keytruda trial in aggressive prostate cancer campaign, takes separate hit in lung cancer</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/roche-her2-franchise-under-pressure-pays-70m-breast-cancer-brain-metastases-prospect">Roche, with HER2 franchise under pressure, pays $70M for breast cancer brain metastases prospect</a></li>
<li><a href="https://www.fiercepharma.com/pharma/takeda-makes-113m-deal-hutchmed-cancer-drug-fruquintinib">Takeda pledges up to $1.13B for rights to Hutchmed's cancer drug fruquintinib outside of China</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/bio-top-lilly-researcher-says-company-looking-closely-glp-1-cessation-impact-its-hard-prove">BIO: Moderna to test mpox vaccine in humans this summer</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/jazz-looking-new-bandmates-amid-piping-hot-ma-market">BIO: Jazz is auditioning new bandmates in an M&amp;A market ripe with talent</a></li>
<li><a href="https://www.fiercepharma.com/pharma/biontech-defend-itself-against-covid-19-vaccine-injury-claims-germany">BioNTech to defend itself against COVID-19 vaccine injury claim in Germany</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/salvation-or-death-warrant-erytechs-war-activist-investor-rumbles-merger-vote-nears">Salvation or 'death warrant'? Erytech's war with activist investor rumbles on as merger vote nears</a></li>
<li><a href="https://www.fiercepharma.com/marketing/rsv-vaccine-awareness-low-among-older-adults-majority-would-ask-their-doc-about-new-shots">RSV vaccine awareness low among older adults, but majority would ask their doc about new shots: survey</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/huma-nabs-fda-nod-ai-backed-disease-management-platform">Huma nabs FDA nod for AI-backed disease management platform</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/medtronic-warns-cardioversion-can-fry-some-vanta-neurostimulators">Medtronic warns cardioversion can fry some Vanta neurostimulators</a></li>
</ul>
"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement